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Abstract: Objectives:  The objective of this cross-sectional study was to assess with adequate
confounding control, whether anticholinergic burden affects cognitive performance in
community-dwelling older adults.
Design:  Prospectively collected International Residential Assessment Instrument-
Home Care (interRAI-HC) assessment data.
Settings and Participants:  Community-dwelling people in New Zealand aged ≥65
years who have undergone a standardized needs assessment between June 2012 and
June 2014 using the interRAI-HC, and who provided consent were included. The dose
calculation from the drug burden index score was applied to a list of  Drugs with
Anticholinergic Properties (DAP) to quantify anticholinergic burden  (DAP-DBI), and the
Cognitive Performance Scale to assess cognitive function. The outcome is the severity
of cognitive impairment determined at the first interRAI-HC assessment as an ordinal-
categorical variable, the severity categories, from the best to the worst are “None”,
“Mild”, “Moderate” and “Severe”. The probability used for the inverse weight is the
probability of non-zero anticholinergic burden (DAP-DBI>0). We constructed an ordinal
regression model based on various demographic, social and clinical characteristics to
assess whether anticholinergic burden affects cognitive performance, in the sample
weighted by the inverse probability of treatment weight (IPTW).
Results:  14,198 individuals received 31994 interRAI assessments. After IPTW
adjustment, baseline characteristics in both groups were balanced (population
standardized bias < 0.20). The ITPW-adjusted ordinal regression model showed a
significant association of poor cognitive performance with anticholinergic burden. 
Odds ratio = 2.53 (95%CI, 1.93-3.31) for DAP-DBI between 0.1 and 0.99, OR = 1.51
(95%CI, 1.14-1.20) for DAP-DBI between 1 and 2.5, and OR = 2.89 (95%CI, 2.18,
3.84) for DAP-DBI above 2.5), comparing to those with zero DAP-DBI.
Conclusions and Implications:  In older adults requiring complex care anticholinergic
burden was associated with poor cognitive performance. Anticholinergic burden is a
modifiable risk factor and should be routinely monitored during geriatric risk
assessments and reduced whenever feasible.
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ABSTRACT 
Objectives: The objective of this cross-sectional study was to assess with adequate 
confounding control, whether anticholinergic burden affects cognitive performance in 
community-dwelling older adults. 
Design: Prospectively collected International Residential Assessment Instrument- Home Care 
(interRAI-HC) assessment data. 
Settings and Participants: Community-dwelling people in New Zealand aged ≥65 years who 
have undergone a standardized needs assessment between June 2012 and June 2014 using the 
interRAI-HC, and who provided consent were included. The dose calculation from the drug 
burden index score was applied to a list of Drugs with Anticholinergic Properties (DAP) to 
quantify anticholinergic burden (DAP-DBI), and the Cognitive Performance Scale to assess 
cognitive function. The outcome is the severity of cognitive impairment determined at the first 
interRAI-HC assessment as an ordinal-categorical variable, the severity categories, from the 
best to the worst are “None”, “Mild”, “Moderate” and “Severe”. The probability used for the 
inverse weight is the probability of non-zero anticholinergic burden (DAP-DBI>0). We 
constructed an ordinal regression model based on various demographic, social and clinical 
characteristics to assess whether anticholinergic burden affects cognitive performance, in the 
sample weighted by the inverse probability of treatment weight (IPTW). 
Results: 14,198 individuals received 31994 interRAI assessments. After IPTW adjustment, 
baseline characteristics in both groups were balanced (population standardized bias < 0.20). 
The ITPW-adjusted ordinal regression model showed a significant association of poor 
cognitive performance with anticholinergic burden.  Odds ratio = 2.53 (95%CI, 1.93-3.31) for 
DAP-DBI between 0.1 and 0.99, OR = 1.51 (95%CI, 1.14-1.20) for DAP-DBI between 1 and 
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2.5, and OR = 2.89 (95%CI, 2.18, 3.84) for DAP-DBI above 2.5), comparing to those with zero 
DAP-DBI. 
Conclusions and Implications: In older adults requiring complex care anticholinergic burden 
was associated with poor cognitive performance. Anticholinergic burden is a modifiable risk 
factor and should be routinely monitored during geriatric risk assessments and reduced 
whenever feasible. 
Introduction 
Older people are particularly susceptible to the adverse effects of anticholinergic burden due 
to advanced age, polypharmacy (≥5 drugs), comorbidities, increased permeability of the blood-
brain barrier, diminished cholinergic reserves in the brain and pharmacokinetic and 
pharmacodynamic alterations slowing drug metabolism and drug clearance 1-7.  
Anticholinergic burden increases the risk of cognitive impairment in older people 8. A recent 
nested case-control study (N= 284,343) conducted in the United Kingdom examined the 
association between anticholinergic burden and risk of dementia 9. This observational study 
accounted for several important confounders identified as risk factors for dementia and 
addressed the risk of protopathic bias by excluding anticholinergic exposures well before the 
date of incident dementia diagnosis. However, the study did not adjust for the baseline 
differences in the clinical characteristics in the case and control groups and for time-dependent 
exposures, and both factors can threaten the validity of the results. A systematic review of the 
literature conducted by Kersten et al. reported mixed associations between high anticholinergic 
burden and cognitive performance in older people 10. Observational studies included in this 
systematic review were either cross-sectional or cohort designed, and nine of the studies found 
no association between anticholinergic burden and cognitive performance. However, a meta-
analysis of 18 studies comprising of prospective cohorts (n = 10), retrospective cohorts (n = 4), 
case-control (n = 2), and randomized control trials (n = 2) reported that exposure to 
anticholinergic burden is associated with an increased risk of cognitive impairment in older 
people 8. 
Non-randomized studies are likely to provide biased estimates of treatment effects as the 
treated and untreated groups may have systematic differences in covariates that may influence 
the study outcomes 11. The inverse treatment probability weight (IPTW) method provides an 
adjusted exposure effect and mitigates confounding by eliminating the strong influence of such 
covariates on the drug exposure 12. 
This study takes advantage of the international residential assessment instrument (interRAI) 
dataset. It was created by an international panel of clinicians and academics and is used in over 
30 countries 13.  There have been several studies presenting that the data is reliable.  New 
Zealand is one of the first countries in the world to mandate the use of the interRAI for all 
people who have complex needs.   
The overarching objective of this study was to examine the association between anticholinergic 
burden and cognitive function in community-dwelling older adults. 
Methods 
Study design 
In this cross-sectional study, we included community-dwelling adults aged ≥65 years with 
interRAI Home Care Assessment System (interRAI-HC) assessment undertaken between 1 
June 2012 and 30 June 2014. The interRAI-HC data has been used extensively for examining 
health outcomes in the population of older adults in NZ 14. This study was approved by the 
Ministry of Health’s Health and Disability Health Committees (ref 15/CEN/45) and only 
includes individuals consented for their anonymised data to be used for research purposes. 
The interRAI–HC assessment includes 236 questions over 20 distinct domains covering 
demographic, clinical, social, psychosocial and environmental assessments.  The interRAI-HC 
instrument has been described in detail elsewhere 14, 15. The data is of good quality and readily 
linked with other data sets. All interRAI assessors complete a three-day training programme. 
The 1.5-hour interRAI assessment includes 236 standardized items which are recorded 
electronically, and all data is stored nationally (14). 
Anticholinergic burden  
We used the reference composite anticholinergic scale derived from a systematic review of the 
literature examining anticholinergic burden in older adults to identify drugs with 
anticholinergic properties (DAPs) 16. We linked prescription data from the PHARMAC 
database with interRAI assessments using the NZ national unique identifier (National Health 
Index or NHI) number. We extracted details of prescriptions and their doses for the included 
anticholinergic drugs 90 days before the assessment date and the drug burden attributable to 
each anticholinergic medication was calculated using the equation, Drug Burden 
Anticholinergic Index (DBI (ACh)) =D/(D+ δ); where D is the daily dose in milligrams taken 
by the individual, and δ is the minimum efficacious dose 17. To obtain the daily dose we divided 
the product of quantity dispensed and weight by 90 days. The anticholinergic burden was 
calculated by summing up the DBI (ACh) for each DAP dispensed to the participant. This 
measure of exposure differs from the anticholinergic component of the validated DBI 18 as the 
validated DBI only includes drugs with clinical anticholinergic effects documented on the 
registered product information, while the DAP list includes a wider list of drugs with possible 
anticholinergic effects.  We only considered oral dosage forms and transdermal fentanyl but 
excluded all other formulations  for calculation of anticholinergic burden. Oxybutynin 
transdermal patch is not funded by PHARMAC and hence not included in the analyses. 
We measured anticholinergic burden within 90 days before the first interRAI-HC assessment, 
and the anticholinergic burden was summarized into four possible categories, DAP-DBI = 0, 
>0 and ≤1, >1 and ≤2.5, and >2.5. 
Cognitive performance 
All participants undertaking an interRAI-HC assessment have their cognition assessed using 
the Cognitive Performance Scale (CPS). The CPS assessment pools information on memory 
impairment, consciousness, and executive function, with scores ranging from 0 (intact) to 6 
(very severe impairment). Several validation studies have found the scores derived from the 
CPS to be highly correlated with the Mini-Mental State Examination (MMSE) scores 19, 20. For 
this study, we categorised individuals into four categories: CPS score 0 and 1-No cognitive 
impairment, 2-mild cognitive impairment, 3-moderate and CPS score >4 with severe cognitive 
impairment. Previous studies have used a cut-off of 2 points or more to define cognitive 
performance and used similar categorizations to define higher degrees of cognitive impairment 
19, 21, 22.  
Covariates variables  
The covariates included in the model were demographic characteristics (age in years, sex, 
marital status, living status), social characteristics (alcohol consumption, smoking status), 
clinical characteristics (chronic obstructive pulmonary disease, coronary heart disease, 
diabetes, stroke, hearing impairment and visual impairment), and self-reported functional 
characteristics (activities of daily living, instrumental activities of daily living, falls history). 
We chose these variables a priori because of their potential association with anticholinergic 
exposure. 
Outcome 
The outcome variable is the severity of cognition impairment determined using the CPS at the 
first interRAI assessment as an ordinal-categorical variable, the severity categories, from the 
best to the worst are “None” (i.e. normal), “Mild”, “Moderate” and “Severe”. 
Inverse probability treatment weighting 
For ITPW, the probability used for the inverse weight is the probability of having a DAP-DBI 
of 0, between 0 and 1 (excluding 0), between 1 and 2.5 (excluding 1), and above 2.5, within 90 
days before the first interRAI assessment. We fitted a multinomial logistic model to calculate 
the above-mentioned probabilities for each individual. We included all covariates in the 
multinomial logistic regression model.  
We checked that covariates are balanced between the 4 DAP-DBI categories after ITPW, so 
that we can be confident that spurious effects of covariates on exposures are sufficiently 
reduced by computing the “population standardized bias” (PSB) for each variable and for each 
DAP-DBI category as described by McCaffrey et al 23.  The covariates are sufficiently balanced 
if all PSBs are no higher 0.20. (Figure 1) 
Ordinal regression 
We calculated the odds ratio of having a worse cognitive impairment due to DAP-DBI exposure 
by ordinal regression with and without ITPW weighting. The outcome of interest is the severity 
of cognitive impairment of an individual, which was coded as an ordinal-categorical variable 
(from 0 for normal cognition, to 3 for severe impairment). We used the function "polr" in the 
R package "MASS" for the ordinal regression model. 
Results 
We derived the final study cohort (N=14,198) from the interRAI-HC information available for 
105,502 assessments for 70,159 individuals (Flow chart). The mean age (SD) of the cohort 
was 82.5 years (7.2), 8,866 (62.4%) were female, and the majority, 12,712 (89.5%), were 
European (Table 1).  
The study cohort included 14,198 individuals who received 31994 assessments. Among the 
study cohort, majority (n = 8148, 57.4%) had no cognitive impairment at baseline, 31.7% (n = 
4503) had mild cognitive impairment, 7.3% (n = 1033) had moderate cognitive impairment, 
and a very low proportion (n = 514, 3.6%) had severe cognitive impairment (Flow chart).  
Demographic, social and clinical characteristics of the study population are shown in Table 1. 
Before covariate balancing, persons with anticholinergic exposure had more comorbidities 
including chronic obstructive pulmonary disease, congestive heart failure, coronary heart 
disease, depression, diabetes, and were fatigued with reduced mobility and recent 
hospitalisations. After ITPW adjustment, baseline characteristics were balanced (population 
standardized bias < 0.20 for all variables and in all DAP-DBI categories (Figure 1) 
The IPTW-adjusted ordinal regression model showed a significant association between 
cognitive performance and anticholinergic exposure. With a DAP-DBI > 2.5, the odds of 
having a worse cognitive outcome is approximately 2.9 times higher (OR = 2.89 (95% CI 2.18-
3.84 with ITPW)) relative to zero DAP-DBI. Significant association of worse cognitive 
outcome and non-zero DAP-DBI were also observed for lower DAP-DBI ranges, with and 
without ITPW (Figure 2). 
Discussion 
This study found an association between anticholinergic exposure and cognitive performance 
in a population of older adults requiring complex care. The study findings are consistent with 
two large cohort studies that have examined an association with anticholinergic burden and 
poor cognitive performance 24, 25. In a large cohort of 13,004 participants aged 65 and older 
living in England and Wales the use of drugs with definite anticholinergic activity was 
associated with a 0.33‐point greater decline in MMSE scores (95% CI, 0.03–0.64) 24. The 
PAQUID cohort study involving 1780 community-dwelling participants aged 70 and older 
living in South Western France reported that short-term exposure to DAPs for 2-weeks was 
associated with low MMSE scores (OR = 1.4; 95% CI 1.0, 2.1) 25. Similarly, a cohort study 
conducted among 372 older adults living in France reported that use of DAPs for more than 1 
year was a strong predictor of mild cognitive impairment (odds ratio 5.12, P = 0.001) 26. Similar 
findings were echoed by Han et al., among 504 community-dwelling men, a 1-unit increase in 
the total anticholinergic burden per 3 months was associated with a 0.32-point (95% confidence 
interval (CI)= 0.05-0.58) decrease in short-term memory measured using the Hopkins Verbal 
Recall Test 27.  
More recently, two longitudinal studies conducted in the United Kingdom reported a dose-
response relationship between anticholinergic burden and risk of dementia in older adults after 
controlling for risk factors for dementia 9, 28. The hazard ratios for the risk of dementia in each 
study were 1.49 (95% CI, 1.44-1.54) 9 and 1.11 (95% CI, 1.08 to 1.14) 28, respectively. We 
cannot directly compare the findings of our study with these two large observational studies 
because of the differences in the study population, dissimilarities in the quantification of 
anticholinergic burden and importantly these studies examined incident dementia as their study 
outcome. 
In comparison to previous cohort studies, a methodological improvement of the current study 
is the use of the IPTW method to diminish bias due to confounding factors that dictate 
exposures, resulting in imbalanced distribution of baseline characteristics across exposure 
groups. Our study has several other strengths, including its large size, unique population 
characteristics, nationwide coverage in NZ, and use of an internationally recognized 
standardized instrument for geriatric risk assessment. Another notable strength of our study is 
that we used a validated pharmacological model-the drug burden index- to quantify the 
anticholinergic burden 18. Previous studies that examined association of cumulative 
anticholinergic use on cognitive performance lacked information about the dose and duration 
of anticholinergic use 24, 26, 29, 30. We accounted for several comorbidities associated with DAP 
use in the multinomial logistic regression model for deriving the IPTW, thus to an extent 
mitigating confounding by indication.   
Our study noted some important limitations. We did not ascertain if individuals prescribed 
DAPs have taken them, nor did we account for over-the-counter DAPs, as these could lead to 
exposure misclassification. Given there is a lack of international consensus and poor 
concordance of currently used scales to measure anticholinergic burden, we used the reference 
composite scale which identified DAPs from already published rating scales used in clinical 
research to quantify anticholinergic burden. The reference composite scale identifies 
isosorbide, metoprolol, metformin, furosemide warfarin, and digoxin as DAPs. These drugs 
are not included in the validated DBI, and maybe appropriate therapies for the treatment of 
coronary heart disease, congestive heart failure, diabetes and stroke which are all risk factors 
for cognitive impairment. The prevalence of a high DAP-DBI> 2.5 exposure is greater than 
that seen in studies of the validated DBI because a much broader range of drugs were defined 
as anticholinergic in the DAP measure.  The lack of dose-response seen with the relationship 
between DAP-DBI and cognitive impairment suggests that this measure of anticholinergic 
burden is not strongly associated with cognitive impairment, and a focus on anticholinergic 
drugs that cross the blood brain barrier may be appropriate to investigate in future studies. 
Another possible explanation for this finding is that anticholinergic drugs may be deprescribed 
in people living with severe cognitive impairment, consistent with studies that reported 
decreased use of PIMs in people living with dementia.   
We calculated anticholinergic burden before the first and second geriatric risk assessments but 
not for the entire study period. However, a previous epidemiological study conducted on the 
same interRAI-HC cohort found that the drug burden as a time-varying covariate did not 
change substantially over the study period 31. Kashyap et al. highlighted critical methodological 
challenges faced in observational studies examining anticholinergic burden and cognitive 
decline 32.  Studies that have reported a raw change in MMSE scores have found a negative 
association 24, while studies that used a clinical definition of cognitive change were less likely 
to find associations with anticholinergic exposure 29. Although several validation studies have 
found that the CPS to be highly correlated with the MMSE scores, it is possible that 
categorization of CPS scores in our study may have misclassified the cognitive status of the 
study participants.  Another limitation of our study is that we followed our cohort for two years, 
and longer duration studies may be required to determine the potential long-term impact of 
anticholinergic burden on cognitive performance. Despite confounding control, this 
observational study only shows associations and the findings do not infer causality.  
Conclusions 
In older New Zealanders requiring complex care high anticholinergic burden was associated 
with poor cognitive performance. Anticholinergic burden is a modifiable risk factor and should 
be routinely monitored during geriatric risk assessments and reduced whenever feasible. 
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With child only 
With non-relatives 
With relative 


















































































































































































































































None within the last 90 
days 
Fell 31-90 days ago 
One fall in the last 30 
days 


































































































































Less than 5 meters 






























None within the last 90 
days 
31-90 days ago 
In the last 30 days 






































































    
 
Initial dataset  
 105502 assessments  
 70159 individuals 
 June 2012 till June 2014 
 
Anomalies (271 assessments) 
 
 Invalid NHI=245 
 Date of death < date of admission=24 
 Died before June 2012=2 




   
Exclusion criteria (73237 assessments) 
 
 64yrs or younger=3599 
 Not living at home=6404 
 Assessment in and beyond Oct 2015=2754 
 ARC within 30d of assessment=10268 
 DOA within 30d of DOD=836 
 DOA before 30 June 2014=22363 






Clean dataset (105231 assessments) 












 31994 assessments 












No exposure DAP−DBI 0−0.99 DAP−DBI 1−2.5 DAP−DBI >2.5





Hopistalisation: Now in hospital
Hopistalisation: In the last 30 days
Hopistalisation: 31−90 days ago
Hopistalisation: None within the last 90 days
Mobility: Did not walk

















Fall history: Two or more in the last 30 days
Fall history: One fall in the last 30 days
Fall history: Fell 31−90 days ago




























Bowel state: Out of control
Bowel state: Continent
Bladder state: Out of control
Bladder state: Continent
Residential state: With spouse and partner only
Residential state: With relatives
Residential state: With non−relatives














Population standardized bias (PSB) = abs(exposure group mean − pooled mean) / pooled SD
Unweighted
ITPW












OR of worse cognition outcome
Reference: No exposure
Ordinal regression with and without ITPWFigure 2
